Agency for Care Effectiveness - ACE

On 13 May 2026, ACE's Consumer Engagement and Education (CEE) team welcomed Consumer Panel members as they begin a new term, during a productive meeting focused on strengthening patient involvement in healthcare decision-making.

Together, we discussed how the Panel can play a greater role in ACE's work including strengthening patient involvement across ACE’s activities, enhancing stakeholder understanding of ACE’s role, maximising the reach and impact of our consumer education efforts, and demonstrating the Panel's influence on healthcare decision-making in Singapore.

A big thank you to all Panel members for your valuable insights and thoughtful suggestions. We look forward to continuing our collaboration to further strengthen patient involvement in health technology assessment (HTA) in Singapore!

Interested in getting more involved in ACE's work? Find out more here: https://go.gov.sg/acefb318

ACE was proud to present at a workshop hosted by the Centre for Innovation in Regulatory Science, held from 3-5 March in Kuala Lumpur! The workshop brought together stakeholders from regulatory agencies, HTA bodies, industry and patient organisations to explore how to build capacity for patient involvement in regulatory and HTA decision-making across the Asia-Pacific region.

Valuable insights were shared during the workshop – Senior Advisor Fiona Pearce presented on global versus Asia-Pacific patient involvement practices, drawing from recent HTAi 360 studies, while Senior Specialist Mr Shawn Quek discussed approaches to building capacity for patient involvement in Singapore's HTA process.

We congratulate CIRS on delivering such an informative session and look forward to future workshops.

👉 Interested in getting involved? Find out more about patient involvement opportunities in Singapore: https://go.gov.sg/acefb317

In a health technology assessment (HTA), the PICO framework, which stands for Population, Intervention, Comparison, and Outcome, is used to define the research question that the HTA aims to answer. It also helps develop clear search terms to find the best available evidence to inform the assessment.

🔍 Learn more about the PICO framework in our new learning module: go.gov.sg/acefb314

Selamat Hari Raya Haji ✨

From all of us at ACE, we wish those celebrating a meaningful and peaceful Hari Raya Haji.

May this occasion bring reflection and a renewed sense of purpose, as we continue working together to improve care for all.

Hypertension is often called a “silent” condition — but its effects are far from invisible.

In Singapore, more than 1 in 3 adults has hypertension, and over half remain undiagnosed. If left unmanaged, it can lead to serious complications such as stroke, heart disease, and kidney damage.

Managing hypertension involves more than just lowering blood pressure. It includes understanding overall cardiovascular risk and taking appropriate steps — from lifestyle changes to treatment where needed.

👉 This World Hypertension Day, read our ACG on hypertension here: https://go.gov.sg/acefb311

🎉We are pleased to share that ACE has published two articles in the International Journal of Technology Assessment in Health Care, highlighting Singapore's journey in strengthening patient involvement in health technology assessment (HTA)!

📄The first publication - "Patient involvement in health technology assessment: a new process in Singapore" describes ACE’s approach to identifying relevant local patient organisations through stakeholder mapping, co-developing processes with these organisations, and building capacity to support meaningful patient input.

📄The second publication - "Establishing a Consumer Panel to Inform Health Technology Assessment Processes and Policy: impact and insights from Singapore's experience", outlines ACE's approach to establishing the Consumer Panel and highlights its contributions. These include co-developing patient involvement processes and educational resources, supporting health literacy efforts, and strengthening collaboration between ACE and patient communities. Panel members Prof Lau Tang Ching and Dr Ritu Jain also contributed to this article as co-authors.

These publications demonstrate ACE’s ongoing efforts to strengthen patient voices in healthcare decision-making.

Click the links below to read the full articles:

1. https://go.gov.sg/acefb308

2. https://go.gov.sg/acefb309

Find out more about how you can contribute to ACE’s work: https://go.gov.sg/acefb310

Immunotherapy is one of the treatment options for advanced non-small cell lung cancer (NSCLC) and several immunotherapy drugs are subsidised in Singapore for this condition.

Learn more about immunotherapy drugs for advanced NSCLC in our latest factsheet: go.gov.sg/acefb295